A radiobiological investigation on dose and dose rate for permanent implant brachytherapy of breast using i 125 or P 103 d sources

Medical Physics

Volumn 37, Issue 6, 2010, Pages 2572-2586

  Baltas, Dimos ^a,b   Lymperopoulou, Georgia ^c   Löffler, Edgar ^d   Mavroidis, Panayiotis ^e,f  

^a Klinikum Offenbach GmbH   (Germany)

^b UNIVERSITY OF ATHENS   (Greece)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^d Ibt Bebig   (Belgium)

^e KAROLINSKA INSTITUTE   (Sweden)

^f UNIVERSITY HOSPITAL OF LARISSA   (Greece)

Author keywords

125I 103Pd; Biologically effective dose; Linear quadratic model; Permanent implants

Indexed keywords

DISEASES; ONCOLOGY; TUMORS;

BIOLOGICALLY EFFECTIVE DOSE; EARLY-STAGE BREAST CANCER; EXTERNAL BEAM RADIOTHERAPY; EXTERNAL RADIOTHERAPY; IMPLANT BRACHYTHERAPY; LINEAR-QUADRATIC MODELS; TUMOR PROLIFERATION; ^125I^103PD;

RADIOTHERAPY;

EID: 77953517664     PISSN: 00942405     EISSN: None     Source Type: Journal    
DOI: 10.1118/1.3426027     Document Type: Article

References (44)

1. H. L. Howe, " Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends.," J. Natl. Cancer Inst. JNCIEQ 0027-8874 93, 824-842 (2001). 10.1093/jnci/93.11.824
2. B. Fisher, " Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.," N. Engl. J. Med. NEJMAG 0028-4793 347, 1233-1241 (2002). 10.1056/NEJMoa022152 (Pubitemid 35176242)
3. F. A. Vicini, " Limited-field radiation therapy in the management of early-stage breast cancer.," J. Natl. Cancer Inst. JNCIEQ 0027-8874 95, 1205-1210 (2003).
4. T. A. King, " Long-term results of wide field brachytherapy as the sole method of radiation therapy after segmental mastectomy for Tis,1,2 breast cancer.," Am. J. Surg. AJSUAB 0002-9610 180, 299-304 (2000). 10.1016/S0002-9610(00)00454-2
5. F. A. Vicini, " Accelerated treatment of breast cancer.," J. Clin. Oncol. JCONDN 0732-183X 19, 1993-2001 (2001).
6. B. M. Keller, J. P. Pignol, E. Rakovitch, Y. R. Sankreacha, and P. O'Brien, " A radiation badge survey for family members living with patients treated with a P 103 d permanent breast seed implant.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 70, 267-271 (2008). 10.1016/j.ijrobp.2007. 08.006
7. V. Sacchini, K. Beal, J. Goldberg, L. Montgomery, E. Port, and B. McCormick, " Study of quadrant high-dose intraoperative radiation therapy for early-stage breast cancer.," Br. J. Surg. BJSUAM 0007-1323 95, 1105-1110 (2008). 10.1002/bjs.6208
8. L. Teymournia, D. Berger, D. Kauer-Dorner, K. Poljanc, W. Seitz, H. Aiginger, and C. Kirisits, " Comparison of PDR brachytherapy and external beam radiation therapy in the case of breast cancer.," Phys. Med. Biol. PHMBA7 0031-9155 54, 2585-2595 (2009). 10.1088/0031-9155/54/8/022
9. M. Guerrero and A. X. Li, " Analysis of a large number of clinical studies for breast cancer radiotherapy: Estimation of radiobiological parameters for treatment planning.," Phys. Med. Biol. PHMBA7 0031-9155 48, 3307-3326 (2003). 10.1088/0031-9155/48/20/004 (Pubitemid 37321554)
10. R. G. Dale, " The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy.," Br. J. Radiol. BJRAAP 0007-1285 58, 515-528 (1985). 10.1259/0007-1285-58-690-515
11. R. G. Dale, " Radiobiological assessment of permanent implants using tumour repopulation factors in the linear-quadratic model.," Br. J. Radiol. BJRAAP 0007-1285 62, 241-244 (1989). 10.1259/0007-1285-62-735-241
12. R. G. Dale, J. H. Hendry, B. Jones, A. G. Robertson, C. Deehan, and J. A. Sinclair, " Practical methods for compensating for missed treatment days in radiotherapy, with particular reference to head and neck schedules.," Clin. Oncol. ZZZZZZ 0305-7399 14, 382-393 (2002). 10.1053/clon.2002.0111
13. B. Jones, R. G. Dale, and A. M. Gaya, " Linear quadratic modeling of increased late normal-tissue effects in special clinical situations.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 64, 948-953 (2006). 10.1016/j.ijrobp.2005.10.016
14. M. Zaider and L. Hanin, " Biologically-equivalent dose and long-term survival time in radiation treatments.," Phys. Med. Biol. PHMBA7 0031-9155 52, 6355-6362 (2007). 10.1088/0031-9155/52/20/017 (Pubitemid 350093198)
15. C. I. Armpilia, R. G. Dale, and B. Jones, " Determination of the optimum dose per fraction in fractionated radiotherapy when there is delayed onset of tumor repopulation during treatment.," Br. J. Radiol. BJRAAP 0007-1285 77, 765-767 (2004). 10.1259/bjr/47388747 (Pubitemid 39386925)
16. O. J. Ott, R. Pötter, J. Hammer, G. Hildebrandt, M. Lotter, A. Resch, U. Pöhls, M. W. Beckmann, R. Sauer, and V. Strnad, " Accelerated partial breast irradiation with iridium-192 multicatheter PDR/HDR brachytherapy. Preliminary results of the German-Austrian multicenter trial.," Strahlenther. Onkol. STONE4 0179-7158 180, 642-649 (2004). 10.1007/s00066-004-1294-2 (Pubitemid 39361962)
17. P. Mavroidis, S. Axelsson, S. Hyödynmaa, J. Rajala, M. A. Pitkänen, B. K. Lind, and A. Brahme, " Effects of positioning uncertainty and breathing on dose delivery and radiation pneumonitis prediction in breast cancer.," Acta Oncol. ACTOEL 0284-186X 41, 471-485 (2002). 10.1080/028418602320405078 (Pubitemid 35222047)
18. P. Mavroidis, M. al-Abany, A. R. Helgason, A. K. Ågren Cronqvist, P. Wersäll, K. Theodorou, C. Kappas, H. Lind, B. K. Lind, G. Steineck, and A. Brahme, " Dose-response relations for anal sphincter regarding fecal leakage and blood or phlegm in stools after radiotherapy for prostate cancer.," Strahlenther. Onkol. STONE4 0179-7158 181, 293-306 (2005). 10.1007/s00066-005-1313-y (Pubitemid 40768419)
19. C. Armpilia, R. G. Dale, P. Sandilos, and L. Vlachos, " Radiobiological modeling of dose-gradient effects in low dose rate, high dose rate and pulsed brachytherapy.," Phys. Med. Biol. PHMBA7 0031-9155 51, 4399-4411 (2006). 10.1088/0031-9155/51/17/018 (Pubitemid 44261852)
20. S. S. Stefanou, R. B. Sparks, and R. G. Dale, " A theoretical investigation into post-operative, intracavitary beta therapy of high-grade glioblastomas using yttrium-90.," Phys. Med. Biol. PHMBA7 0031-9155 51, 5377-5389 (2006). 10.1088/0031-9155/51/20/020 (Pubitemid 44540138)
21. W. M. Butler, R. R. Stewart, and G. S. Merrick, " A detailed radiobiological and dosimetric analysis of biochemical outcomes in a case-control study of permanent prostate brachytherapy patients.," Med. Phys. MPHYA6 0094-2405 36, 776-787 (2009). 10.1118/1.3077161
22. B. S. Rosenstein, S. C. Lymberis, and S. C. Formenti, " Biologic comparison of partial breast irradiation protocols.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 60, 1393-1404 (2004). 10.1016/j.ijrobp. 2004.06.156
23. J. P. Pignol, B. Keller, E. Rakovitch, R. Sankreacha, H. Easton, and W. Que, " First report of a permanent breast P 103 d seed implant as adjuvant radiation treatment for early-stage breast cancer.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 64, 176-181 (2006). 10.1016/j.ijrobp.2005. 06.031
24. N. Jansen, J. M. Deneufbourg, and P. Nickers, " Adjuvant stereotactic permanent seed breast implant: A boost series in view of partial breast irradiation.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 67, 1052-1058 (2007). 10.1016/j.ijrobp.2006.10.031
25. J. P. Pignol, E. Rakovitch, B. M. Keller, R. Sankreacha, and C. Chartier, " Tolerance and acceptance results of a palladium-103 permanent breast seed implant Phase I/II study.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 73, 1482-1488 (2009). 10.1016/j.ijrobp.2008.06.1945
26. B. Keller, R. Sankreacha, E. Rakovitch, P. O'Brien, and J. P. Pignol, " A permanent breast seed implant as partial breast radiation therapy for early-stage patients: A comparison of palladium-103 and iodine-125 isotopes based on radiation safety considerations.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 62, 358-365 (2005). 10.1016/j.ijrobp.2004.10.014
27. C. G. Orton and F. Ellis, " A simplification in the use of the NSD concept in practical radiotherapy.," Br. J. Radiol. BJRAAP 0007-1285 46, 529-537 (1973). 10.1259/0007-1285-46-547-529
28. C. G. Orton and B. M. Webber, " Time-dose factor (TDF) analysis of dose rate effects in permanent implant dosimetry.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 2, 55-60 (1977). 10.1016/0360-3016(77)90008-6
29. D. Baltas, L. Sakelliou, and N. Zamboglou, The Physics of Modern Brachytherapy for Oncology (CRC/Taylor & Francis, New York/London, 2007).
30. W. T. Millar, " Application of the linear-quadratic model with incomplete repair to radionuclide directed therapy.," Br. J. Radiol. BJRAAP 0007-1285 64, 242-251 (1991). 10.1259/0007-1285-64-759-242
31. R. G. Dale and B. Jones, " The clinical radiobiology of brachytherapy.," Br. J. Radiol. BJRAAP 0007-1285 71, 465-483 (1998).
32. R. W. Howell, S. M. Goddu, and D. V. Rao, " Proliferation and the advantage of longer-lived radionuclides in radioimmunotherapy.," Med. Phys. MPHYA6 0094-2405 25, 37-42 (1998). 10.1118/1.598171 (Pubitemid 28063686)
33. V. Antipas, R. G. Dale, and I. P. Coles, " A theoretical investigation into the role of tumor radiosensitivity, clonogen repopulation, tumour shrinkage and radionuclide RBE in permanent brachytherapy implants of I 125 and P 103 d.," Phys. Med. Biol. PHMBA7 0031-9155 46, 2557-2569 (2001). 10.1088/0031-9155/46/10/304 (Pubitemid 32982395)
34. C. I. Armpilia, R. G. Dale, I. P. Coles, B. Jones, and V. Antipas, " The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 55, 378-385 (2003). 10.1016/S0360-3016(02)04208-6 (Pubitemid 36069096)
35. C. C. Ling, " Permanent implants using Au-198, Pd-103 and I-125: Radiobiological considerations based on the linear quadratic model.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 23, 81-87 (1992). 10.1016/0360-3016(92)90546-T
36. M. A. R. Alexander, W. A. Brooks, and S. W. Blake, " Normal tissue complication probability modeling of tissue fibrosis following breast radiotherapy.," Phys. Med. Biol. PHMBA7 0031-9155 52, 1831-1843 (2007). 10.1088/0031-9155/52/7/005 (Pubitemid 46646349)
37. R. M. Wyatt, A. H. Beddoe, and R. G. Dale, " The effects of delay in radiotherapy treatment on tumour control.," Phys. Med. Biol. PHMBA7 0031-9155 48, 139-155 (2003). 10.1088/0031-9155/48/2/301 (Pubitemid 36204153)
38. J. Yarnold, A. Ashton, J. Bliss, J. Homewood, C. Harper, J. Hanson, J. Haviland, S. Bentzen, and R. Owen, " Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: Long-term results of a randomised trial.," Radiother. Oncol. RAONDT 0167-8140 75, 9-17 (2005). 10.1016/j.radonc.2005.01.005 (Pubitemid 40616788)
39. B. Jones and R. Dale, " Mathematical models of tumour and normal tissue response.," Acta Oncol. ACTOEL 0284-186X 38, 883-893 (1999). 10.1080/028418699432572
40. A. P. Dicker, C. C. Lin, D. B. Leeper, and F. M. Waterman, " Isotope selection for permanent prostate implants? An evaluation of P 103 d versus I 125 based on radiobiological effectiveness and dosimetry.," Semin Urol. Oncol. ZZZZZZ 1081-0943 18, 152-159 (2000).
41. P. T. Finger, K. J. Chin, and G. Duvall, " Palladium-103 ophthalmic plaque radiation therapy for choroidal melanoma: 400 treated patients.," Ophthalmology OPHTDG 0161-6420 116, 790-796 (2009). 10.1016/j.ophtha.2008.12.027
42. G. W. Barendsen, " Dose fractionation, dose rate and iso-effect relationships for normal tissue responses.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 8, 1981-1997 (1982). 10.1016/0360-3016(82)90459-X
43. C. C. Ling, W. X. Li, and L. L. Anderson, " The relative biological effectiveness of I-125 and Pd-103.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 32, 373-378 (1995). 10.1016/0360-3016(95)00530-C
44. R. G. Dale, B. Jones, and J. A. Sinclair, " Dose equivalents of tumour repopulation during radiotherapy: The potential of confusion.," Br. J. Radiol. BJRAAP 0007-1285 73, 892-894 (2000).